M1395 Initial Chemotherapy (HCPCS) Reimbursement | OpenPayer

Summary & Overview

HCPCS M1395: Initial Chemotherapy Regimen with Defined Duration

HCPCS Level II code M1395 represents an initial chemotherapy regimen with a defined duration delivered by an eligible clinician or group. The code captures the start of a planned chemotherapy course and the associated management during the defined regimen period. Its use is important nationally as oncology care increasingly emphasizes episode-based billing, care coordination, and clear documentation of planned treatment durations.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how M1395 is defined and applied in clinical and billing workflows, summaries of payer coverage considerations, and context on how the code fits into episode-based chemotherapy delivery. The publication outlines benchmarks and common implementation issues relevant to oncology practices and outpatient infusion centers, and highlights policy and documentation aspects that affect claim acceptance and clinical coding consistency.

This summary provides actionable clarity on the purpose of M1395, what sites and services it most commonly represents, and what stakeholders should expect when the code is present on a claim. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1395HCPCS Level IIchemotherapyoncologyinfusionoutpatientepisode-based caretreatment regimenbilling

Billing Code Overview

HCPCS Level II code M1395 denotes services for patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group. This code describes an episode-based oncology service focused on initiating a chemotherapy plan with an expected treatment timeframe.

Service type: Chemotherapy initiation and regimen management
Typical site of service: Oncology clinic or outpatient infusion center

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 62-year-old female with newly diagnosed stage IIIB hormone receptor–negative, HER2-negative breast cancer is referred to medical oncology for initiation of a planned multi-agent chemotherapy regimen with a defined duration under the treating clinician or group. The oncology team performs an initial consultation visit, documents the agreed regimen (for example, six cycles of dose-dense doxorubicin/cyclophosphamide followed by paclitaxel), obtains baseline labs (CBC, CMP), arranges central venous access placement when indicated, and schedules infusion appointments. The patient receives education on expected toxicities and supportive care (antiemetics, growth factor support) and signs informed consent for chemotherapy. The initial chemotherapy regimen is administered in the outpatient oncology infusion center; the clinician documents the treatment plan, cycle schedule, drug selection, dosing, and duration in the medical record to support billing with M1395. Typical workflow steps: pre-treatment evaluation and staging review, baseline labs and imaging as needed, consent and regimen selection, vascular access placement if required, first-cycle infusion with monitoring, and coordinated scheduling for subsequent cycles.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when initial chemotherapy planning or administration requires substantially greater work, documentation, or time than usual (e.g., complex dosing calculations, prolonged management).

HCPCS Level II M1146: Ongoing Care Not Clinically Indicated, Home Program/Referral

HCPCS-M1500-NEUROPSYCHOLOGY-MIPS-VALUE-PATHWAY

HCPCS M1500: Neuropsychology MIPS Value Pathway

HCPCS-M1306-ANAPHYLAXIS-PNEUMOCOCCAL-VACCINE-HISTORY

HCPCS Level II M1306: Anaphylaxis Due to Pneumococcal Vaccine

HCPCS-M1458-PATIENT-DIED-PERFORMANCE-PERIOD

HCPCS M1458: Patient Died Prior to End of Performance Period

HCPCS-M1378-COLORECTAL-SURVEILLANCE-INTERVAL-JUSTIFICATION

HCPCS M1378: Documentation of Medical Reason for Not Recommending 10-Year Follow-Up

HCPCS-M1155-ANAPHYLAXIS-PNEUMOCOCCAL-VACCINE

HCPCS M1155: Anaphylaxis Due to Pneumococcal Vaccine, Documented

HCPCS-M1214-SPIROMETRY-CONFIRMED-AIRFLOW-OBSTRUCTION

HCPCS M1214: Spirometry with Confirmed Airflow Obstruction, Documented and Reviewed

HCPCS-M1197-ITCH-SEVERITY-ASSESSMENT-SCORE-IMPROVEMENT

HCPCS M1197: Itch Severity Assessment, 3+ Point Improvement

HCPCS-M1175-DOCUMENTATION-ZOSTER-VACCINE-CONTRAINDICATION

HCPCS Level II M1175: Documentation of Medical Reason for Not Administering Zoster Vaccine

HCPCS-M1468-HEPATITIS-B-VACCINATION-COMPLETED-AGE-APPROPRIATE-DOSES

HCPCS M1468: Hepatitis B Vaccination, Age-Appropriate Doses

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
207RG0100X	Medical Oncology	Primary specialty responsible for chemotherapy regimen selection, consent, and management.
207RH0000X	Hematology	Involvement when hematologic malignancy or complex cytopenia management is required.
207T00000X	Radiation Oncology	May coordinate care when concurrent chemoradiation is planned; documents multi-modality regimen.
363L00000X	Vascular Surgery	Performs placement of long-term vascular access when interventional placement is required.
371K00000X	Interventional Radiology	Performs image-guided central venous access placement for chemotherapy delivery.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.912`	Malignant neoplasm of unspecified site of right female breast	Common primary diagnosis for initiating a defined chemotherapy regimen in breast cancer.
`C50.911`	Malignant neoplasm of unspecified site of left female breast	As above for left-sided disease requiring systemic chemotherapy.
`C34.90`	Malignant neoplasm of unspecified site of unspecified part of bronchus or lung	Lung cancer often requires a defined initial systemic chemotherapy regimen.
`C83.9`	Non-Hodgkin lymphoma, unspecified	Hematologic malignancies commonly begin an initial chemotherapy regimen with documented duration.
`C61`	Malignant neoplasm of prostate	Advanced or metastatic prostate cancer may receive defined-duration systemic chemotherapy in select cases.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`38100`	Splenectomy; total (separate operative procedure)	Data not available in the input.
`36460`	Hemodialysis catheter insertion, non-tunneled central venous catheter; without subcutaneous port or pump, age 5 years or older	Used for temporary central venous access when immediate short-term infusion is required prior to placement of a tunneled port.
`36561`	Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump	Commonly used for placement of a tunneled catheter to provide vascular access for the chemotherapy regimen.
`36568`	Insertion of tunneled centrally inserted central venous catheter, with subcutaneous port, age 5 years or older	Used when placing an implanted port-a-cath to support repeated chemotherapy infusions in a defined regimen.
`99204`	Office or other outpatient visit for the evaluation and management of a new patient, typically 45 minutes	Often represents the initial oncology consultation when selecting and initiating a defined chemotherapy regimen.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Represents administration of chemotherapy agents during the initial infusion cycles as part of the documented regimen.

OpenPayer